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Introduction
Smoldering (asymptomatic) multiple myeloma (SMM) is defined as having a monoclonal protein (M-protein) of 3g/dl (30g/l) or urinary monoclonal protein ≥500mg/24h and/or 10-60% bone marrow clonal plasma cells and no end-organ damage (1). Although a recent clinical trial showed that high risk SMM patients may benefit from early treatment before multiple myeloma (MM) criteria are met, guidelines recommend a "watchful waiting" approach using M-protein, routine biochemistry and blood count as well as skeletal survey, preferably MRI, for follow-up every 4-6 or 6-12 months, depending on disease stability (1-3).
Current risk models for progression from SMM to MM include presence of immunoparesis (reduction in one or more of the uninvolved immunoglobulin), aberrant plasma cell percentage (PC)% > 95% (defined by flow cytometry) and bone marrow PC% (BMPC%) ≥ 10% together with abnormal free light chain ratio (FLCr) and M-protein ≥ 30g/l (4) (5) (6) . Recently, chromosomal aberrations and focal bone marrow lesions on MRI have also been used to define progression risk in SMM (7, 8) . Furthermore, a new 4-gene (GEP4) high risk SMM signature (SWOG S0120) has been developed by the Arkansas Group (9) . However, currently there is no consensus on how to classify low, intermediate or high risk SMM and one study has shown discrepancies between major risk models when applied to the same cohort (10) .
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The aim of this population-based study was to assess risk factors for progression to multiple myeloma in SMM patients using the Danish Multiple Myeloma Registry (DMMR), which includes information on all diagnosed SMM patients in Denmark since 2005.
Methods

Study population
The DMMR is population-based, covering all new multiple myeloma cases in Denmark since 1 January 2005 (11, 12) . Symptomatic MM patients in the DMMR are defined according to 
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date of diagnosis of SMM with no progression/events and excluded 9 patients due to early death and 2 patients due to early progression. This led to a study population of 321 SMM patients (Table 1) . We defined immunoparesis as at least one uninvolved immunoglobulin below reference levels IgG < 6.1 g/l, IgA < 0.70 g/l and/or IgM < 0.39 g/l at diagnosis.
Statistics
The sample size of our cohort was found to be acceptable for investigating factors associated with progression. With a power of 0.8 and a two-sided level of significance of 0.05, a Hazard ratio of 1.9 is needed to find a significant association. Baseline characteristics were described using median, interquartile range (IQR) and range for continuous variables and by frequencies and percentages. Proportional hazard assumption and linearity of continuous variables were investigated. Univariable Cox regression analysis was used to estimate risk factors for time to progression (TTP) with hazard ratios (HR) and 95% CI.
Significant univariable risk factors were selected for multivariable Cox regression analyses.
First, all significant risk factors were entered in a model and afterwards a backward selection method was used to eliminate insignificant risk factors. The Kaplan-Meier method was then used for estimation of progression rate.
All statistical analyses were performed using SPSS ver. 
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Results
Three-hundred-twenty-one of 2879 MM patients met the criteria for SMM, corresponding to 11% of the total Danish MM population. This is slightly lower than observed in a recent Swedish analysis that reported a SMM prevalence of 14.4% of all myeloma patients in line with previous studies (14, 15) . The median age at diagnosis was 70 years and the malefemale ratio was 46% (males) to 54% (females) ( Table 1) 
Prognostic factors for disease progression to MM:
Univariable risk factors for TTP were tested for all 321 SMM cases. Sixty-one patients progressed to MM within a median follow up time of 729 days (median TTP not reached).
The total number of patients that progressed at 2 years was 50, which was equivalent to 82% of all patients who progressed within the follow-up period (IQR 383-1376 days). Results for TTP are shown in Table 1 . Of notice high clonal BMPC % was a significant risk factor for progression (p = 0.02) using PC% as continuous variable but BMPC % was not significant when defined as ≥ 10% versus < 10% (HR 0.8 (0.2;3.3) p=0.75). High M-protein level at diagnosis was a risk factor for TTP, in particular, when immunoglobulin levels were above
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Risk of progression at 2 years was 5%, 18% and 38% for a score of 0, 1 or 2 risk factors, respectively, and increased to 9%, 24% and 55%, respectively, at 5 years from diagnosis (Figure 1, P<0 .001, table III). We tested the same risk stratification on the population using the new IMWG criteria for SMM. Exclusion of these "ultra-high risk" SMM patients (n=26) with BM PC >60% or FLCr ≥ 100 did not affect the risk stratification, in fact, the risk of
This article is protected by copyright. All rights reserved. progression at 2 years was then 4%, 17% and 44% with the score 0, 1 or 2, respectively (p<0.0001). Furthermore, the impact of FLCr was tested in a multivariable analysis on the subgroup of patients with FLC registered (n=209). Multivariable cox regression using near significant (p<0.2) univariable values immunoparesis, M-protein level ≥ 30 g/l, abnormal FLCr, BMPC% and albumin levels did not change the impact of FLCr on TTP (HR 1.1 p=0.86).
In this subgroup we did not find FLCr to be an independent risk factor for TTP.
Discussion
We report the first population-based, large retrospective cohort study on independent risk factors for progression in smoldering multiple myeloma. In line with previous single center studies, we found that M-protein ≥ 30g/l and presence of immunoparesis are markers for time to progression to MM in SMM.
There is increasing knowledge on risk factors for progression in myeloma precursor 
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This article is protected by copyright. All rights reserved. difference between patients with 25% reduction as compared to those with 50% or 75% reduction (hazard ratios 3.5, 2.5 and 2.6, respectively). Suppression of two versus one uninvolved immunoglobulins indicated a higher risk of progression in our study; however, the differences in HR were limited (Table 2 ). Our findings support and simplify immunoparesis as a risk factor of progression in SMM: suppression of one uninvolved immunoglobulin below normal level is sufficient to identify increased risk of progression to multiple myeloma.
Dispenzieri et al. showed that PC % > 10 had a higher impact on progression than both Mprotein > 3g/dl and abnormal FLCr (5) . In contrast, we found that a PC% ≥ 10 did not contribute as an independent risk factor in our cohort. However, this result is questionable, as only 5 of our patients had PC % < 10 at diagnosis, leaving the statistical power too low to detect any differences. We showed that high PC % was a significant risk factor for progression as a continuous value; however, it failed in the multivariate analysis and could therefore not be included in our risk score (Table 1 ). In line with the IMWG diagnostic criteria, the bone marrow PC % was, in our cohort, estimated using the highest value of either the bone marrow biopsy stained with hematoxylin and eosin, the bone marrow aspirate or from the bone marrow imprint at the time of diagnosis. The Mayo Clinic study used an average of the aspirate and biopsy estimates of PC % which could therefore possibly result in a lower median PC count than in our cohort (5, 17) .
The updated IMWG criteria includes FLCr ≥ 100 (with involved FLC > 100mg/l) and BMPC % > 10 as a criterion for MM. This recommendation was based on 2 studies that showed 76% and nearly 100% 2-year progression risk in SMM patients with FLCr ≥ 100, respectively (6, 18) . The goal for IMWG to change the definitions was to identify SMM patients that have
a ≥ 80% risk of progression to myeloma within 2 years. Upfront treatment of these patients should be considered to avoid early onset of irreversible organ damage, e.g. bone destruction. In our population-based study, we found that 23 patients fulfilling these criteria had only a 30% 2-year progression risk for symptomatic MM (figure 2). A risk below 80% of progression to MM, namely a 64% risk, was also observed in the recent study by Waxman et al. (19) . Patients with high FLCr are probably at increased risk of development of renal affection and should be carefully observed. However, our data and the Waxman study do not support FLCr above 100 as a stand-alone ultra-high risk criterion. 
g/dl to define SMM patients with a 81% risk of progression within 2 years after diagnosis (19) . Only three patients in our cohort fulfilled these high risk criteria (none progressed to MM within the follow-up), and we are therefore not able to validate the Penn model risk classification. Low albumin level did correlate to increased risk of progression (albumin cont.
HR 0.5, p=0.01)) in univariable analysis; however, albumin was not an independent risk factor in the multivariable analysis (Tables I and II ).
The Penn model is based on single center observations. Here, we introduce the first population-based prognostic scoring system using two easily assessable markers; immunoparesis and M-protein level. Our risk score is simple, easily performed, and does not require advanced diagnostics. Examinations of aberrant PC markers by flow cytometry, cytogenetics and gene expression profiling are not available at all centers. Importantly, our risk score also proved robust in patients still identified as SMM patients after introduction of the updated IMWG SMM criteria (1), although we do not have data on how many patients that would have been classified as symptomatic MM due to the MRI criteria of more than one bone marrow focal lesion. We recommend that patients with our definition of high risk SMM should be observed more carefully and considered candidates for randomized clinical trials. Twenty-three patients (11%) had a FLCr ≥ 100 (or FLCr ≤ 0.01) and iFLC >100mg/l, and 186 patients had FLCr 0.01-100. The 2-year (24 months) progression risk was 30.4% (95CI 5.4%;48.8%) with a HR = 2.4 (1.0;5.9), p=0.06 for the patients with FLCr ≥ 100.
